Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because — once again — that oh-so-predictable routine of meetings, deadlines, calls, and the like has returned. But what can you do? The world keeps spinning, yes? So time to get cracking, brew another cup of stimulation, and climb another mountain. To help you along, we have assembled a few tidbits. Hope your day goes well and do keep in touch. …

The Food and Drug Administration approved an Amag Pharmaceuticals (AMAG) drug to restore sexual desire in pre-menopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra,” STAT writes. The therapy will compete in a market that has seen previous attempts fail. The drug, called Vyleesi, activates pathways in the brain involved in sexual desire, helping pre-menopausal women with hypoactive sexual desire disorder. But one pundit argues the FDA erred by lowering the approval bar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!